- Home
- CLLS
CLLS
Cellectis S.A.
as 03-28-2025 3:33pm EST
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
| Founded: | 1999 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 148.1M | IPO Year: | 2007 |
| Target Price: | $7.00 | AVG Volume (30 days): | 833.7K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.14 - $3.38 | Next Earning Date: | 03-13-2025 |
| Revenue: | $49,217,000 | Revenue Growth: | 435.38% |
| Revenue Growth (this year): | 1.26% | Revenue Growth (next year): | -48.33% |
Latest Cellectis S.A. News
CLLS Breaking Stock News: Dive into CLLS Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Discover European Penny Stocks: I.M.D. International Medical Devices And 2 More To Watch
GlobeNewswire
16 days ago
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
GlobeNewswire
22 days ago
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
GlobeNewswire
23 days ago
Monthly information on share capital and company voting rights
GlobeNewswire
a month ago
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
GlobeNewswire
2 months ago
Monthly information on share capital and company voting rights
GlobeNewswire
2 months ago
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
MT Newswires
2 months ago
Cellectis Files for Resale of 44 Million Company Shares by AstraZeneca
Compare CLLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLLS Cellectis S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.